Abstract Irinotecan has radiosensitizing effects and shows synergism with nitrosoureas. We performed a Phase II study of RT and irinotecan, followed by BCNU plus irinotecan in newly-diagnosed GBM. The MTD for patients receiving enzyme-inducing anticonvulsants (EIAC) was as follows: irinotecan 400 mg/m 2 /week on 7.7-14.9); OS at 12 months was 44.6% (95% CI: 33.3-59.8) and PFS 6 was 28.6% (95% CI: 18.9-43.2). Patients went off treatment due to adverse events (7%), refusal (11%), progressive disease (48%), death (9%), and other (9%); 16% completed protocol treatment. Survival was similar in patients with variant (6/7 or 7/7) and wild-type (6/6) UGT1A1*28 genotypic alleles. Grade 3-4 toxicity was more common in non-EIAC patients with variant alleles. SN-38 C max and AUC in EIAC patients receiving 400 mg/m 2 irinotecan were 20.9 ng/ml and 212 ng/ml h, and in non-EIAC patients receiving 125 mg/m 2 , 15.5 ng/ ml and 207 ng/ml h. SN-38 AUC varied by UGT1A1*28 status in non-EIAC patients. This regimen was not significantly active and radiosensitization was not observed. Non-EIAC patients with UGT1A1*28 variant alleles appear particularly sensitive to toxicity from irinotecan.
Introduction
In preclinical models, irinotecan has radiosensitizing effects, and produces additive cytotoxicity when combined with nitrosoureas [1] [2] [3] [4] [5] . This Phase II study (NCCTG N997D) evaluated the safety and efficacy of radiotherapy (RT) and concomitant irinotecan, followed by adjuvant BCNU plus irinotecan in patients with newly diagnosed glioblastoma (GBM). The primary goals were to determine the maximum tolerated dose in patients receiving and not receiving enzyme-inducing anticonvulsants (EIAC), and to evaluate the efficacy of the regimen utilizing a primary endpoint of overall survival at 12 months (OS12).
Methods
An initial pilot study was performed order to determine the MTD for patients not receiving (Arm A) and receiving (Arm B) enzyme-inducing anticonvulsants (EIAC).The Phase II study (Arm C) included all patients (EIAC and non-EIAC) treated at the MTD. All patients signed an informed, written consent to participate in the study, and the protocol was reviewed and approved by the Institutional Review Boards of each participating institution.
Radiotherapy (5000 cGy) was administered in 200 cGy/ day fractions to the initial fields, consisting of the area of localized contrast enhancement or mass and surrounding edema as estimated from the postoperative MRI or CT scan plus a 2 cm margin. A final boost of 1000 cGy, administered in 200 cGy/day fractions, was then administered to the area of contrast enhancement plus a 2 cm margin. Radiotherapy was administered in 5 fractions per week for 6 weeks.
Eligibility criteria included a histologic diagnosis of newly diagnosed glioblastoma (WHO Grade 4 astrocytoma) confirmed by pre-registration central review by an NCCTG neuropathologist; recovery from effects of surgery; age C 18; ECOG performance status 0-2; absolute neutrophil count C1500/mm 3 , platelet count C130000/ mm 3 , serum creatinine B0.5 mg/dl above the upper limit of normal (ULN), total bilirubin B1.5 times the ULN; SGOT (AST) B2 times ULN. Patients were ineligible if they were or had received prior RT or chemotherapy; pregnant or nursing; unwilling to use adequate contraception if of childbearing potential; Grade 4 oligodendroglioma or mixed oligoastrocytoma; uncontrolled infection; co-existent malignant disease (other than superficial skin cancers); or significant other medical illnesses.
Dose limiting toxicity (DLT) was defined as the inability to deliver at least three of four planned doses of irinotecan during RT due to drug-related grade C4 diarrhea or myelosuppression, or severe neurological deterioration not responsive to corticosteroids. Dose de-escalations (but not escalations) were allowed. Toxicity was graded by the NCI Clinical Toxicity Criteria (CTC version 2.0).
The primary endpoint for the pilot study was to determine the maximum tolerated doses (MTD) for non-EIAC and EIAC patients. The primary endpoint for the Phase II study was overall survival at 12 months (OS12). The Phase II study was a one-stage design, and included two interim efficacy analyses after 35 and 60 eligible patients were followed for one year. The a priori decision rule required that 18 patients met criteria for success, which was defined as being alive one year after the start of therapy. The planned target accrual for the Phase II trial was 84 eligible patients. The a priori decision rules used for the interim and final analyses were based on a 3-stage Fleming version of Simon's Optimum 2-Stage design for testing the null hypothesis. The survival experience was compared by logrank test with that previously observed utilizing a set of patients pooled from five previous NCCTG trials involving newly-diagnosed GBM (79-72-51, 85-72-51, 88-72-52, 93-72-52, and 98-72-52). The proportion of patients alive at 12 months from this historical database was 0.50. The sample size was determined to achieve an overall one-sided significance level of 0.10 with power of 0.90 for detecting a proportion of patients alive at 12 months of 0.65 or greater. The overall time-to-event distributions (survival and progression-free survival) were estimated using the method of Kaplan-Meier [6] . Overall survival (OS) was defined as time from start of study therapy to death from any cause. Progression-free survival (PFS) was defined as time from start of study therapy to documentation of disease progression. Patients who died without documented progression were considered as having progressed at time of death. Patients who had not died or progressed at the time of analysis were censored at the date of last follow-up.
Response was defined by NCCTG criteria as previously described [7] . Response had to be sustained on two consecutive MRI or CT scans at least 4 weeks apart. Patients progressing on two consecutive neurological exams C4 weeks apart were considered as having progressed, regardless of scan findings. UGT1A1*28 genotyping (6/6, wild type; 6/7, heterozygote; 7/7, dual variant allele) was performed on tumor tissues obtained at initial surgery. Statistical comparisons were made between genotype (6/6, 6/7, 7/7) and outcome categories of response (complete or partial response, regression, stable, progression, unknown); survival (OS12, PFS6); time to event (survival and progression); and drug tolerability (reasons for off treatment; number of cycles; frequency of Grade 3? adverse events). Two analyses were performed, one comparing all three genotypes, and one comparing wild type (6/6) versus mutated (6/7 ? 7/7) genotypes.
For the pharmacokinetic analyses, blood samples were obtained prior to and at the end of initial infusion, and at 1, 2, 4 and 24 h following the end of infusion, placed on ice, and plasma was separated and stored at -70°C until assay. Plasma samples were assayed by high performance liquid chromatography as previously described [8] . Irinotecan, APC and unconjugated SN-38 concentrations were determined by direct analysis of plasma. Total SN-38 concentrations were determined after hydrolysis of SN-38G to SN-38 by incubation with b-glucuronidase and represent the sum of unconjugated SN-38 and conjugated SN-38. SN-38G concentrations estimated by the difference between total SN-38 concentration and the unconjugated SN-38 concentration.
Irinotecan, SN-38, SN-38G and APC plasma concentration data were analyzed by non-compartmental methods (WINNONLIN v4.1, Pharsight, Mountain View, CA).The apparent terminal elimination rate constants (k z ) were determined by linear least-squares regression through the 4 and 24 h plasma-concentration time points. The apparent elimination half-life (t 1/2 ) was calculated as 0.693/k z . Area under the plasma concentration-time curves (AUC 0-24 h ) was determined using the linear trapezoidal rule from time zero to the 24 h sample time. Area under the plasma concentration-time curves through infinite time (AUC 0-? ) was calculated by adding C T /k z to AUC 0-24 h . The clearance of irinotecan was calculated as dose/AUC 0-? , where dose is the administered dose of irinotecan expressed in free base equivalents.
Results
The baseline characteristics of the 56 treated patients (Arm A-20; Arm B-12; Arm C-24) are presented in Table 1 (Table 2) .
Phase II study (Arm C)
Efficacy analysis
At the first interim analysis, the decision rule (18 successes) was not met (14 successes, 19 failures and 2 with incomplete data); thus, further accrual was stopped. In the 56 treated patients, the OS12 was 44.6% (95% CI: 33.3-59.8). Median OS was 10.8 months (95% CI: 7.7-14.9) and was not superior to that observed in our historical database ( Fig. 1a ; P-value = 0.69). The PFS6 was 28.6% (95% CI: 18.9-43.2); PFS-survival rate at 12 months was 14.3% (95% CI: 7.5-27.1), and median PFS was 3.9 months (95% CI: 3.2-5.1). PFS was inferior to that observed in our historical database ( Fig. 1b ; P-value = 0.04). Responses in 38 patients with measurable post-op disease included 1 PR (3%), 7 with regression not meeting PR criteria, (18%) and (Fig. 2) . The most common Grade 3? adverse events were neutropenia, leukopenia, fatigue, diarrhea, and dehydration. There was one Grade 5 event, a patient who died from complications of a gastric ulcer. Twenty-two of the 44 (50%) patients experienced the Grade 3 event prior to disease progression, and 17 (39%) were able to restart active treatment.
Correlation of UGT1A1*28 status with outcome
Specimens were available for UGT1A1*28 genotyping from 42 patients. Of these, both alleles were wild type (6/6) in 16 (38%) patients; one variant allele (6/7) was detected in 22 (52%), and both variant alleles (7/7) detected in 4 (10%). Two analyses were performed, first comparing all three groups, and second, comparing the group of wildtype-allele patients with the group of patients with either one or both variant alleles. There were no significant differences in age, gender, ECOG performance status (0, 1, 2), EIAC use, steroid use, or extent of resection between 6/6, 7/7 or 7/7 patients. No significant differences were observed in best response, OS12, PFS6, progression status, or vital status as a function of genotype (Fig. 3) . Overall, no differences in drug tolerability were observed as a function of genotype. However, in the subgroup of non-EIAC patients with 6/7 or 7/7 genotypes, Grade 3? adverse events were more frequent, as compared to the wild type 6/ 6 patients (P = 0.011). Also, the time to development of the first Grade 3? event, regardless of attribution, varied as a function of UGT1A1*28 genotype (6/6 vs. 6/7 vs. 7/7, P = 0.005); 6/6 vs. 6/7 ? 7/7 P = 0.03). This difference was mostly accounted for by the non-EIAC patients (6/6 vs. 6/7 vs. 7/7, P = 0.05; 6/6 vs. 6/7 ? 7/7, P = 0.02). The frequency of Grade 3 adverse events in EIAC patients did not vary by genotype (6/6 vs. 6/7 vs. 7/7, P = 0.15; 6/6 vs. 6/7 ? 7/7, P = 0.82). The pharmacokinetics of irinotecan and its metabolites were characterized in 27 patients from both cohorts to establish the effect of anticonvulsant usage and UGT1A1*28 genotype (Table 3) irinotecan was identical to the mean clearance value of 20.9 l/h/m 2 for EIAC patients, receiving 400 mg/m 2 irinotecan. Similarly, concurrent treatment with EIAC did not appear to substantially affect the formation and elimination of SN-38G. SN-38G C max and AUC values were only threefold greater for patients receiving EIAC as compared to those not receiving EIAC. In contrast, concurrent treatment with EIAC had a greater effect on formation of the metabolite carbonyloxycamptothecin (APC). The APC C max and AUC values were eightfold greater in EIAC patients as compared to patients not receiving EIAC. Concurrent treatment with EIAC also had a pronounced affect on formation and elimination of the active metabolite, SN-38 (7-ethyl-10-hydroxy camptothecin). Mean C max and AUC values of 20.9 ng/ml and 212 ng/ml h, respectively, for EIAC patients were not much greater than the mean C max and AUC values of 15.5 ng/ml and 207 ng/ml h, A modest effect of genotype on SN-38 AUC was observed in non-EIAC patients. SN-38 AUC was higher and SN-38G AUC was lower in patients homozygous for the UGT1A1 variant allele (7/7) as compared with patients homozygous for the wild type allele (6/6).
Discussion
Irinotecan is a pro-drug that exerts its action after conversion by a carboxyl esterase to an active metabolite, SN-38 (7-ethyl-10-hydroxy camptothecin). Irinotecan is also metabolized to an inactive metabolite, carbonyloxycamptothecin (APC), via the hepatic p450-microsomal enzyme CYP3A4. SN-38 is inactivated by glucuronidation, via the uridine-diphosphate glucuronyltransferase isoenzyme (UGT1A1) [9] . An inherited gene polymorphism of UDP-glucuronosyltransferase (UGT1A1*28) may result in reduced metabolism of SN-38, and subsequent increase in drug-related toxicity at conventional doses [10, 11] .
Prior studies of glioma patients on EIACs have reported significant reductions in SN-38 exposure (AUC) following irinotecan administration [12] [13] [14] [15] . Patients receiving EIACs often require 2-4 times greater dosage than non-EIAC patients to achieve the same SN-38 exposure. The MTD of irinotecan was determined to be 117 mg/m 2 in non-EIAC patients, and 419 mg/m 2 weekly in patients receiving EIACs [16] . Using an every 3-week regimen, the MTD was established at 750 mg/m 2 for EIAC patients, and 350 mg/ m 2 for non-EIAC patients [17] . LEUKOPENIA  LYMPHOPENIA  MEMORY LOSS  MUSCLE WEAKNESS  NAUSEA  NEUTROPENIA  EDEMA  DYSPHAGIA  NEURO-MOTOR  THROMBOCYTOPENIA  PNEUMONITIS  PROTHROMBIN TIME  PULMONARY FIBROSIS  THROMBOSIS  VOMITING  INCONTINENCE  NEUTROPENIA-BMT  LEUKOPENIA-PEDS  SKIN IRRITATION  STOMATITIS-BMT  INFECTION-UNK ANC  INFECTION- We previously evaluated two different dose schedules of irinotecan in recurrent glioma patients [8] . The first tested 100-125 mg/m 2 weekly for 4 weeks, repeated every 6 weeks; the second tested 250-300 mg/m 2 every 3 weeks. Tumor response (PR) was observed in 6.5% (2/32) in each cohort. Lower mean concentrations and AUC of both irinotecan and its metabolites were observed in EIAC patients. In other studies, response rates to irinotecan have been 0-15%, with OS varying from 4 to 8.5 months [18] [19] [20] [21] .
There are limited clinical data regarding co-administration of RT and irinotecan. In a study of newly-diagnosed locally advanced non-small cell lung cancer patients, the response rate to RT plus concurrent irinotecan and cisplatin was 83%, with a median survival of 20.1 months [22] . In a prior Phase II study involving newly-diagnosed GBM patients, RT plus irinotecan followed by adjuvant BCNU plus irinotecan (adjusted for EIAC status) produced minor responses in 3/25 (12%) of patients; toxicities included neutropenia (26%), asthenia (13%) and diarrhea (8%) [23] . In another study, GBM patients receiving RT and concurrent temozolomide and irinotecan had a median PFS and OS of 7.7 and 12.8 months [20] .
Pre-clinical studies have reported radiation sensitizing effects of irinotecan in lung and colon carcinoma cell lines and xenografts [1, 4, 5] . Irinotecan and carmustine have also shown synergism in human glioma xenografts [2, 3] .
In the correlative analysis, patients not receiving EIAC with UGT1A1*28 6/7 or 7/7 variant alleles more frequently developed Grade 3 or greater toxicity, and experienced a shorter time to development of such toxicity than EIAC patients. We suspect that the lack of toxicity in the variant patients receiving EIAC may result from significant induction of CYP3A4 with enhanced metabolism of irinotecan. These results suggest that consideration be given to testing for the presence of UGT1A1*28 variant alleles, if not receiving EIAC.
The pharmacokinetics of irinotecan and its metabolites for both EIAC and non-EIAC patients were similar to those observed in a prior Phase I study [16] . Plasma concentrations of SN-38 achieved in both cohorts were equal to or greater than the concentrations used in vitro to enhance radiation-induced cytotoxicity [1, 4] . However, SN-38 exposure achieved in both cohorts were lower than the exposure in mice (AUC 534 ng/ml h) administered a single dose of 10 mg/kg irinotecan that was associated with radiosensitization [1, 24] . The impact of the UGT1A1*28 polymorphism on irinotecan pharmacokinetics and toxicity is highly dependent on dose, with lower toxicity and AUC following administration in a weekly schedule [25, 26] .
Data from this study were not mature until after the EORTC randomized Phase III study was reported, which showed a survival benefit for the combination of RT plus concomitant and adjuvant temozolomide (TMZ) over RT alone [27] . At the time of design of the current study, nitrosourea-based regimens were considered standard for front line therapy for newly-diagnosed GBM patients. BCNU had been shown to produce superior survival when combined with RT as compared to RT ? methylprednisolone alone [28] , and evidence of combined efficacy with RT was reported in a meta-analysis of existing prospective studies [29] . There has been some resurgence of discussion regarding nitrosoureas, largely due to unanticipated findings resulting from follow-up analyses involving long term glioma survivors. Although needing validation, recent analyses have hinted at a beneficial effect in long-term survivors when comparing RT with nitrosourea-based regimens (largely procarbazine, CCNU and vincristine, PCV) to RT alone for low-grade glioma [30] , and even when compared with RT ? TMZ for anaplastic oligodendroglioma [31] . Furthermore, the outcome of anaplastic glioma patients, as measured by time to second relapse, does not differ between patients receiving RT followed by chemotherapy (either temozolomide or CCNU) at relapse, or with temozolomide or CCNU initially, followed by RT at relapse [32] . Despite these interesting data, the results from our current study do not support replacement of current therapy with the nitrosourea-based regimen that we utilized in this study. There has been longstanding interest in the potential radiosensitizing effects of irinotecan. In addition, recent studies have combined irinotecan with bevacizumab for recurrent GBM [33] , and RT ? bevacizumab for newly diagnosed GBM. To date, it is not clear that irinotecan produces additive benefit to bevacizumab alone; however, should this prove to be the case, the MTD of the irinotecan ? RT, as determined in this study, may be helpful in construct of future trials involving these agents in combination.
We conclude that in treatment of patients with newly diagnosed GBM, concomitant RT and irinotecan and adjuvant irinotecan plus BCNU does not show greater efficacy than prior NCCTG regimens or current TMZcontaining regimens, and is more toxic. We did not observe clinically relevant radiosensitizing effects. Finally, patients who exhibit marked toxicity with irinotecan may harbor UGT1A1*28 variant alleles, and in particular, caution is advised when utilizing these agents in patients not receiving EIACs.
